Search
vTv Therapeutics Inc
VTVTAdd to Watchlist
31.690USD
+0.020+0.06%
Close 07-23 16:00（ET）Quotes delayed by 15 min
124.82MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-23The current earnings forecast score of vTv Therapeutics Inc is 8.40, ranking 127 out of 386 in the Biotechnology & Medical Research industry. The average price target is 36.00, with a high of 40.00 and a low of 35.00.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
56.400
Target Price
+71.38%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
495
Total
6
Median
7
Average
Company name
Ratings
Analysts
vTv Therapeutics Inc
VTVT
5
Beigene Ltd
ONC
28
argenx SE
ARGX
27
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is vTv Therapeutics Inc's expected revenue for the next quarter?
vTv Therapeutics Inc's expected revenue is 300.00K.
What is vTv Therapeutics Inc's price target?
Analysts forecast that vTv Therapeutics Inc's price target is USD 36.00, with the highest forecast at USD 40.00 and the lowest forecast at USD 35.00.
How have vTv Therapeutics IncVTVT's recent earnings per share performed?
The market expectation was USD 1.94, while vTv Therapeutics IncVTVT's earnings per share (EPS) for the previous quarter was USD -0.57. EPS for the next quarter is expected at USD -0.99.
What is the analyst rating for vTv Therapeutics Inc?
Based on the ratings of vTv Therapeutics Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.